Published online Apr 6, 2024. doi: 10.12998/wjcc.v12.i10.1830
Peer-review started: January 1, 2024
First decision: January 21, 2024
Revised: January 28, 2024
Accepted: March 11, 2024
Article in press: March 11, 2024
Published online: April 6, 2024
Processing time: 91 Days and 13.3 Hours
Moyamoya syndrome (MMS) is a group of diseases that involves more than one underlying disease and is accompanied by moyamoya vascular phenomena. Psoriasis is a chronic immune skin disease closely linked to high blood pressure and heart disease. However, psoriasis-related MMS has not been reported.
We collected data on patients with stroke due to MMS between January 2017 and December 2019 and identified four cases of psoriasis. Case histories, imaging, and hematological data were collected. The average age of the initial stroke onset was 58.25 ± 11.52 years; three cases of hemorrhagic and one case of ischemic stroke were included. The average duration from psoriasis confirmation to the initial MMS-mediated stroke onset was 17 ± 3.56 years. All MMS-related stenoses in
Psoriasis may be a potential risk factor for MMS. Patients with psoriasis should be screened for MMS when they present with neurological symptoms.
Core Tip: As we all known that moyamoya syndrome (MMS) is a special subtype of intracranial arterial disease. Herein, we analyzed the clinical characteristics and prognosis of MMS-related ischemic and hemorrhagic stroke in patients with psoriasis retrospectively, and also, analyzed the probable mechanisms of psoriasis-related MMS, so as to make a reference for diagnosis and early etiology treatment. Finally we suspect that psoriasis may be a potential risk factor of MMS formation. Whereby, we considered that MMS should be screened in patients with psoriasis when they presented neurological symptoms.